Reynold Panettieri, MD
Pulmonary Disease · New Brunswick, NJNPI 1104830629
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 58.4% of the total. 2025 is the largest year on record at $307,001, 2.2 times the $141,917 reported in 2019. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 741 payments — averaging $1363.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$589K
- Regeneron Healthcare Solutions, Inc.$165K
- Sanofi$107K
- Genentech USA, Inc.$35K
- Astrazeneca UK Limited$22K
- GSK$21K
- plus $70K from 13 others
Across 59 payments — averaging $25,623 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$803K
- Astrazeneca AB$218K
- Genentech, Inc.$205K
- AstraZeneca$164K
- Teva Pharmaceuticals USA, Inc.$59K
- Pfizer$24K
- plus $38K from 5 others
What the payments were for
- Consulting fees$311,03031%
- Speaking & faculty fees$596,08959%
- Grants$3,0000%
- Travel & lodging$85,6478%
- Food & beverage$14,1721%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 481 | $589,385 |
| Regeneron Healthcare Solutions, Inc. | 97 | $165,374 |
| Sanofi | 60 | $106,995 |
| Genentech USA, Inc. | 38 | $35,072 |
| Astrazeneca UK Limited | 8 | $22,275 |
| GSK | 16 | $20,507 |
| Merck | 13 | $13,849 |
| Astrazeneca AB | 3 | $9,776 |
| Boehringer Ingelheim | 3 | $7,100 |
| Teva Pharmaceuticals USA, Inc. | 3 | $6,907 |
| Novartis | 4 | $6,626 |
| Sage Therapeutics, LLC | 2 | $5,400 |
| Amgen | 3 | $4,600 |
| Genentech, Inc. | 1 | $4,480 |
| Regeneron | 3 | $4,170 |
| Mylan Specialty L.p. | 3 | $3,806 |
| Chiesi USA, Inc. | 1 | $1,800 |
| Sanofi Pasteur Inc. | 1 | $1,773 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$212,426
- DUPIXENT$211,301
- TEZSPIRE$117,992
- AIRSUPRA$95,780
- BREZTRI$32,157
- XOLAIR$20,936
- NUCALA$7,259
- TRELEGY ELLIPTA$5,525
- ProAir Digihaler$4,500
- Yupelri$3,756
- SPIRIVA RESPIMAT$3,600
- SPIRIVA$3,500
- ADACEL$1,773
How this compares
$1,009,995 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 27 | $130,689 |
| Fasenra PenBenralizumab | 21 | $121,705 |
| Dupixent PenDupilumab | 12 | $51,573 |
| Spiriva RespimatTiotropium Bromide | 25 | $16,799 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $7,400 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,321 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,962 |
| DuleraMometasone/Formoterol | 11 | $3,944 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,385 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,550 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,360 |
| Zafirlukast | 11 | $549 |
| Roflumilast | 11 | $547 |
| Azithromycin | 24 | $464 |
| Fluticasone Propionate | 19 | $350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $589,385 | $137,01042 claims |
| Boehringer IngelheimSpiriva Respimat | $7,100 | $16,79925 claims |
| MerckDulera | $13,849 | $3,94411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in New Brunswick
- Amar BukhariNew Brunswick$21K
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.